Literature DB >> 34074731

Metabolism and Hepatotoxicity of Pyrazinamide, an Antituberculosis Drug.

Zahir Hussain1, Junjie Zhu1, Xiaochao Ma2.   

Abstract

Pyrazinamide (PZA) is an important component of a standard combination therapy against tuberculosis. However, PZA is hepatotoxic, and the underlying mechanisms are poorly understood. Biotransformation of PZA in the liver was primarily suggested behind its hepatoxicity. This review summarizes the knowledge of the key enzymes involved in PZA metabolism and discusses their contributions to PZA hepatotoxicity. SIGNIFICANCE STATEMENT: This review outlines the current understanding of PZA metabolism and hepatotoxicity. This work also highlights the gaps in this field, which can be used to guide the future studies on PZA-induced liver injury.
Copyright © 2021 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34074731      PMCID： PMC8407665          DOI： 10.1124/dmd.121.000389

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN： 0090-9556            Impact factor:   3.579


  34 in total

1.  Xanthine oxidoreductase depletion induces renal interstitial fibrosis through aberrant lipid and purine accumulation in renal tubules.

Authors:  Toshio Ohtsubo; Kiyoshi Matsumura; Kanae Sakagami; Koji Fujii; Kazuhiko Tsuruya; Hideko Noguchi; Ilsa I Rovira; Toren Finkel; Mitsuo Iida
Journal:  Hypertension       Date:  2009-08-10       Impact factor: 10.190

2.  Metabolism of pyrazinamide. Pyrazinamide deamidase of animal tissues.

Authors:  I Toida
Journal:  Am Rev Respir Dis       Date:  1973-04

3.  Association of POR and PPARα polymorphisms with risk of anti-tuberculosis drug-induced liver injury in Western Chinese Han population.

Authors:  Chunying Zhang; Lin Jiao; Hao Bai; Zhenzhen Zhao; Xuejiao Hu; Minjin Wang; Tao Wu; Wu Peng; Tangyuheng Liu; Jiajia Song; Juan Zhou; Mengjiao Li; Mengyuan Lyv; Jingwei Zhang; Hao Chen; Jie Chen; Binwu Ying
Journal:  Infect Genet Evol       Date:  2019-12-16       Impact factor: 3.342

4.  Pharmacokinetics of pyrazinamide and its metabolites in healthy subjects.

Authors:  C Lacroix; T P Hoang; J Nouveau; C Guyonnaud; G Laine; H Duwoos; O Lafont
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

5.  Xanthine dehydrogenase: An old enzyme with new knowledge and prospects.

Authors:  Cheng-Hua Wang; Chong Zhang; Xin-Hui Xing
Journal:  Bioengineered       Date:  2016-08-18       Impact factor: 3.269

6.  In vitro oxidation of pyrazinamide and allopurinol by rat liver aldehyde oxidase.

Authors:  Y Moriwaki; T Yamamoto; Y Nasako; S Takahashi; M Suda; K Hiroishi; T Hada; K Higashino
Journal:  Biochem Pharmacol       Date:  1993-09-14       Impact factor: 5.858

7.  A novel mechanism underlies the hepatotoxicity of pyrazinamide.

Authors:  Tung-Yuan Shih; Chien-Yi Pai; Ping Yang; Wen-Liang Chang; Ning-Chi Wang; Oliver Yoa-Pu Hu
Journal:  Antimicrob Agents Chemother       Date:  2013-01-28       Impact factor: 5.191

8.  Enhanced xanthine oxidase activity in mice treated with interferon and interferon inducers.

Authors:  P Ghezzi; M Bianchi; A Mantovani; F Spreafico; M Salmona
Journal:  Biochem Biophys Res Commun       Date:  1984-02-29       Impact factor: 3.575

Review 9.  Safety of rifampin and pyrazinamide for the treatment of latent tuberculosis infection.

Authors:  Jason E Stout
Journal:  Expert Opin Drug Saf       Date:  2004-05       Impact factor: 4.250

10.  Association of PXR and CAR Polymorphisms and Antituberculosis Drug-Induced Hepatotoxicity.

Authors:  Yu Wang; Xi Xiang; Wei-Wei Huang; Andrew J Sandford; Shou-Quan Wu; Miao-Miao Zhang; Ming-Gui Wang; Guo Chen; Jian-Qing He
Journal:  Sci Rep       Date:  2019-02-18       Impact factor: 4.379
View more
  2 in total

Review 1.  HIV Infection Predisposes to Increased Chances of HBV Infection: Current Understanding of the Mechanisms Favoring HBV Infection at Each Clinical Stage of HIV Infection.

Authors:  Silvere D Zaongo; Jing Ouyang; Yaling Chen; Yan-Mei Jiao; Hao Wu; Yaokai Chen
Journal:  Front Immunol       Date:  2022-04-01       Impact factor: 8.786

2.  Pyrazinamide Resistance and pncA Mutation Profiles in Multidrug Resistant Mycobacterium Tuberculosis.

Authors:  Dawei Shi; Qiulong Zhou; Sihong Xu; Yumei Zhu; Hui Li; Ye Xu
Journal:  Infect Drug Resist       Date:  2022-08-30       Impact factor: 4.177
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.